A Phase 4 interventional study of Ezetimibe and Placebo in Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-05-24.
Sponsored by Organon and Co · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.
Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 46th largest by enrollment of the 97 interventional ones that give a count, is one of 2 that started in 2012, is one of 31 in phase 4, and was the 69th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 20–100
Daiichi Sankyo · Sites in Germany, Italy, Spain
Ages 18+
Punjab Institute of Cardology · Sites in Pakistan
Ages 18+
By country, each count listing its studies:
Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 20 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 152 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 148 across the 97 interventional studies. Of the 91 that completed or were terminated, 47 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 98 have an industry lead sponsor. The 10 most frequent:
This study is registered under Organon and Co, one of the names counted as Organon & Co.. Under that name alone:
Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
91 studies in Hypercholesterolemia by Organon & Co.: none open now, none under way, none of them phase 3. Of 91 finished, 43 (47%) have results posted.
Among the 91 studies in Hypercholesterolemia by Organon & Co., this one is the 54th largest by enrollment of the 81 interventional ones that give a count, is the only one that started in 2012, is one of 19 in phase 4, and was the 80th registered.
Organon & Co.’s Hypercholesterolemia studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 98 studies testing ezetimibe in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Organon & Co.’s 91 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will examine the effect of ezetimibe on glucose metabolism in participants with Type 2 diabetes and hypercholesterolemia.The primary hypothesis is that change in glycated hemoglobin (HbA1c) from baseline in the ezetimibe treatment group will be non-inferior to the placebo control group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
10 mg oral dose once daily for 24 weeks
Drug: Ezetimibe
Placebo to match ezetimibe orally once daily for 24 weeks
Drug: Placebo
10 mg oral dose once daily for 24 weeks
Also known as: MK-0653, SCH 058235
Placebo to match ezetimibe orally once daily for 24 weeks.
Change in Glycated Hemoglobin (HbA1c) From Baseline
HbA1c is blood marker used to report average blood glucose levels over a prolonged period of time and is reported as a percentage (%). HbA1C was measured at baseline and after 24 weeks of study drug administration.
Time frame: Baseline and Week 24
Change in Glycoalbumin From Baseline
Glycoalbumin is a blood marker used to assess blood glucose control over time and is reported as a percentage (%). Serum glycoalbumin levels were assessed at baseline and after 24 weeks of study drug administration.
Time frame: Baseline and Week 24
Change in Fasting Plasma Glucose (FPG) From Baseline
Plasma glucose levels were assessed after an overnight fast at baseline and after 24 weeks of study drug administration.
Time frame: Baseline and Week 24
Percentage of Participants With Adverse Event (AE) "Exacerbation of Diabetes"
The Investigator took into account a participant's index of blood glucose control, diabetes medications, and compliance to diet and exercise therapy to assess overall control of the participant's diabetes and to determine if the participant's diabetes worsened. Participants who experienced the AE "Exacerbation of Diabetes " (verbatim term) were recorded.
Time frame: up to 24 weeks
Percentage of Participants With Changes in Diabetes Medications Due to Worsening of Diabetes
The percentage of participants who had changes to their medications used to treat their diabetes, other than small changes in insulin dosing (± 5 Units), were reported and summarized.
Time frame: Up to 24 weeks
Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline
LDL-C levels measured at baseline and after 24 weeks of treatment
Time frame: Baseline and Week 24
Percent Change in Total Cholesterol (TC) From Baseline
TC levels measured at Baseline and after 24 weeks of treatment.
Time frame: Baseline and Week 24
Percent Change in Triglycerides From Baseline
Triglycerides levels measured at baseline and after 24 weeks of treatment.
Time frame: Baseline and Week 24
Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline
HDL-C levels measured at baseline and after 24 weeks of treatment.
Time frame: Baseline and Week 24
Percent Change in Non-HDL-cholesterol From Baseline
Non-HDL-C levels measured at baseline and after 24 weeks of treatment.
Time frame: Baseline and Week 24
| Milestone | Ezetimibe | Placebo |
|---|---|---|
| Started | 75 | 77 |
| Completed | 74 | 76 |
| Not completed | 1 | 1 |
| Withdrew: Adverse event | 1 | 1 |
HbA1c is blood marker used to report average blood glucose levels over a prolonged period of time and is reported as a percentage (%). HbA1C was measured at baseline and after 24 weeks of study drug administration.
| Percent | Ezetimibe | Placebo |
|---|---|---|
| Change in Glycated Hemoglobin (HbA1c) From Baseline | 0.22 (0.11 to 0.34) | 0.14 (0.03 to 0.25) |
Glycoalbumin is a blood marker used to assess blood glucose control over time and is reported as a percentage (%). Serum glycoalbumin levels were assessed at baseline and after 24 weeks of study drug administration.
| Percent | Ezetimibe | Placebo |
|---|---|---|
| Change in Glycoalbumin From Baseline | -0.02 (-0.37 to 0.34) | -0.02 (-0.37 to 0.33) |
Plasma glucose levels were assessed after an overnight fast at baseline and after 24 weeks of study drug administration.
| mg/dL | Ezetimibe | Placebo |
|---|---|---|
| Change in Fasting Plasma Glucose (FPG) From Baseline | 6.6 (1.1 to 12.1) | 11.4 (6.1 to 16.7) |
The Investigator took into account a participant's index of blood glucose control, diabetes medications, and compliance to diet and exercise therapy to assess overall control of the participant's diabetes and to determine if the participant's diabetes worsened. Participants who experienced the AE "Exacerbation of Diabetes " (verbatim term) were recorded.
| Percentage of Participants | Ezetimibe | Placebo |
|---|---|---|
| Percentage of Participants With Adverse Event (AE) "Exacerbation of Diabetes" | 9.3 | 7.8 |
The percentage of participants who had changes to their medications used to treat their diabetes, other than small changes in insulin dosing (± 5 Units), were reported and summarized.
| Percentage of Participants | Ezetimibe | Placebo |
|---|---|---|
| Percentage of Participants With Changes in Diabetes Medications Due to Worsening of Diabetes | 9.3 | 5.2 |
LDL-C levels measured at baseline and after 24 weeks of treatment
| Percent Change | Ezetimibe | Placebo |
|---|---|---|
| Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline | -22.79 (-25.81 to -19.78) | -1.75 (-4.73 to 1.24) |
TC levels measured at Baseline and after 24 weeks of treatment.
| Percent Change | Ezetimibe | Placebo |
|---|---|---|
| Percent Change in Total Cholesterol (TC) From Baseline | -15.01 (-17.34 to -12.68) | -1.47 (-3.77 to 0.84) |
Triglycerides levels measured at baseline and after 24 weeks of treatment.
| Percent Change | Ezetimibe | Placebo |
|---|---|---|
| Percent Change in Triglycerides From Baseline | -7.52 (-14.97 to -0.08) | 3.83 (-3.57 to 11.23) |
HDL-C levels measured at baseline and after 24 weeks of treatment.
| Percent Change | Ezetimibe | Placebo |
|---|---|---|
| Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline | 3.86 (0.77 to 6.96) | 1.41 (-1.64 to 4.47) |
Non-HDL-C levels measured at baseline and after 24 weeks of treatment.
| Percent Change | Ezetimibe | Placebo |
|---|---|---|
| Percent Change in Non-HDL-cholesterol From Baseline | -21.32 (-24.05 to -18.59) | -2.25 (-4.95 to 0.45) |
Collected over up to 24 weeks for non-serious adverse events (AEs); up to 28 weeks for serious AEs. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ezetimibe | — | 2/75 (2.7%) | 17/75 (22.7%) |
| Placebo | — | 5/77 (6.5%) | 25/77 (32.5%) |
| Event | Ezetimibe | Placebo |
|---|---|---|
| CATARACTEye disorders | 1/75 | 0/77 |
| ABDOMINAL PAIN UPPERGastrointestinal disorders | 1/75 | 0/77 |
| ANGINA PECTORISCardiac disorders | 0/75 | 1/77 |
| ANGINA UNSTABLECardiac disorders | 0/75 | 1/77 |
| ACCIDENTAL OVERDOSEInjury, poisoning and procedural complications | 0/75 | 1/77 |
| ANKLE FRACTUREInjury, poisoning and procedural complications | 0/75 | 1/77 |
| SPINAL OSTEOARTHRITISMusculoskeletal and connective tissue disorders | 0/75 | 1/77 |
| Event | Ezetimibe | Placebo |
|---|---|---|
| NASOPHARYNGITISInfections and infestations | 11/75 | 13/77 |
| TYPE 2 DIABETES MELLITUSMetabolism and nutrition disorders | 7/75 | 6/77 |
| HYPOGLYCAEMIAMetabolism and nutrition disorders | 2/75 | 7/77 |
| PHARYNGITISInfections and infestations | 0/75 | 4/77 |
| Age, Continuous(years) | Ezetimibe | Placebo | Total |
|---|---|---|---|
| Mean | 59.3 ± 10.8 | 60.0 ± 9.7 | 59.6 ± 10.2 |
| Sex: Female, Male(Participants) | Ezetimibe | Placebo | Total |
|---|---|---|---|
| Female | 29 | 29 | 58 |
| Male | 46 | 48 | 94 |
No study locations are listed for this record.
Plan to share: No
Ran from Jul 2012 to primary completion in Jan 2014, 18 months.
Results were first posted in Dec 2014, 11 months after primary completion.
Of 40 phase 4 interventional studies under Hypercholesterolemia, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 18 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ezetimibe